Search

Your search keyword '"Varettoni M"' showing total 326 results
Start Over Author "Varettoni M"
326 results on '"Varettoni M"'

52. A revised international prognostic score system for Waldenström’s macroglobulinemia

Author

Kastritis, E. Morel, P. Duhamel, A. Gavriatopoulou, M. Kyrtsonis, M.C. Durot, E. Symeonidis, A. Laribi, K. Hatjiharissi, E. Ysebaert, L. Vassou, A. Giannakoulas, N. Merlini, G. Repousis, P. Varettoni, M. Michalis, E. Hivert, B. Michail, M. Katodritou, E. Terpos, E. Leblond, V. Dimopoulos, M.A.

Abstract

A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised staging system could better capture prognosis of WM patients in the chemoimmunotherapy era. We developed a revised system based on data from 492 symptomatic patients with at least 3 years and a median of 7 years of follow up while an independent validation cohort included 229 symptomatic patients. We identified age (≤65 vs 66–75 vs ≥76 years), b2-microglobulin ≥ 4 mg/L, serum albumin 65 years and

Published
2019

55. Major responses in MYD88 wildtype (MYD88WT) waldenstrom macroglobulinemia (WM) patients treated with bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111).

Author

Osman M., Chan W.Y., Schneider J., Huang J., Cohen A., Tam C.S., Dimopoulos M., Opat S., Lee H.-P., Cull G., D'Sa S., Owen R., Tedeschi A., Garcia Sanz R., Varettoni M., Buske C., LeBlond V., Osman M., Chan W.Y., Schneider J., Huang J., Cohen A., Tam C.S., Dimopoulos M., Opat S., Lee H.-P., Cull G., D'Sa S., Owen R., Tedeschi A., Garcia Sanz R., Varettoni M., Buske C., and LeBlond V.

Abstract

Background: BTK inhibitors have been shown to be highly active in patients with WM harboring the MYD88L265P mutation, however lower response rates and shorter survival have been reported in patients that lack such mutations (i.e MYD88WT; N Engl J Med 2015;372:1430- 1440). Zanubrutinib is a potent, specific, and irreversible oral investigational BTK inhibitor with a favorable pharmacokinetic profile resulting in complete and sustained BTK inhibition in blood and lymph nodes. Preliminary studies have identified a high response rate with 41.4% of unselected patients achieving a very good partial response [VGPR]) or better (Tam et al, IWWM-10, 2018). Zanubrutinib is currently being evaluated in several ongoing international Phase 3 studies, including two head-to head studies comparing to ibrutinib. Aim(s): Assess the safety and efficacy of zanubrutinib in WM patients with MYD88WT. Method(s): Reported here are data from an exploratory cohort of patients with treatment-na?ve (TN) or relapsed/refractory (R/R) WM in an open-label, multicenter, randomized phase 3 study. Bone marrow MYD88 and CXCR4 mutations were assessed centrally at study entry (NeoGenomics Laboratory). The MYD88 mutation assay used in this study detects all mutations in the region encompassing amino acid Ala260- Pro278, which includes the predominant mutation in WM, MYD88L265P. Mutation detection in the MYD88 amplicon includes a wildtype-allele-blocking approach resulting in enhanced sensitivity (limit of Detection [LOD] 0.5%; Int J Lab Hematol 2016;38:133-140]); compared to a standard polymerase chain reaction/bi-directional Sanger sequencing assay used to detect CXCR4 mutations (LOD 10-15%). Patients were assigned to Cohort 1 (MYD88 mutated; randomized) or Cohort 2 (MYD88WT; non-randomized) based on the MYD88 mutation assay results. All Cohort 2 patients were assigned zanubrutinib 160 mg twice daily until disease progression. Responses were assessed monthly by IgM with extramedullary disease assessment e

Published
2019

56. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Recchia, A. G., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Martino, E. A., Vigna, E., Tripepi, G., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Jaksic, O., Olivieri, J., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., Gentile M., Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Recchia, A. G., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Martino, E. A., Vigna, E., Tripepi, G., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Jaksic, O., Olivieri, J., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2019

59. IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY

Author

Castillo, J., primary, Itchaki, G., additional, Paludo, J., additional, Varettoni, M., additional, Buske, C., additional, Eyre, T., additional, Chavez, J., additional, Shain, K., additional, Issa, S., additional, Palomba, L., additional, Pasvolsky, O., additional, Simpson, D., additional, Talaulikar, D., additional, Tam, C., additional, Tedeschi, A., additional, Ansell, S., additional, Nayak, L., additional, and Treon, S., additional

Published
2019
Full Text
View/download PDF

60. PF614 PATIENT-REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB-RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

Author

Tedeschi, A., primary, Dimopoulos, M.A., additional, Trotman, J., additional, García-Sanz, R., additional, Macdonald, D., additional, Mahe, B., additional, Herbaux, C., additional, Heffner, L.T., additional, Tam, C.S., additional, Varettoni, M., additional, Palomba, M.L., additional, Matous, J.V., additional, Shustik, C., additional, Kastritis, E., additional, Treon, S.P., additional, Li, J., additional, Poulsen, E.G., additional, Hauns, B., additional, Buske, C., additional, and Leblond, V., additional

Published
2019
Full Text
View/download PDF

61. PF392 MONOCLONAL GAMMOPATHY AND HYPOGAMMAGLOBULINEMIA AS INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTRIC EXPERIENCE

Author

Corbingi, A., primary, Innocenti, I., additional, Tomasso, A., additional, Pasquale, R., additional, Visentin, A., additional, Varettoni, M., additional, Autore, F., additional, Morelli, F., additional, Trentin, L., additional, Reda, G., additional, and Laurenti, L., additional

Published
2019
Full Text
View/download PDF

62. PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Author

Tedeschi, A., primary, Dimopoulos, M.A., additional, Trotman, J., additional, García-Sanz, R., additional, Macdonald, D., additional, Mahe, B., additional, Herbaux, C., additional, Heffner, L.T., additional, Tam, C.S., additional, Varettoni, M., additional, Palomba, M.L., additional, Matous, J.V., additional, Shustik, C., additional, Kastritis, E., additional, Treon, S.P., additional, Li, J., additional, Poulsen, E.G., additional, Hauns, B., additional, Buske, C., additional, and Leblond, V., additional

Published
2019
Full Text
View/download PDF

63. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Author

Tedeschi, A, Picardi, P, Ferrero, S, Benevolo, G, Margiotta, Casaluci, G, Varettoni, M, Baratè, C, Motta, M, Gini, G, Goldaniga, Mc, Visco, C, Zaja, Francesco, Belsito Petrizi, V, Ravelli, E, Gentile, M, Urbano, Ma, Franceschetti, S, Ghione, P, Orsucci, L, Frustaci, Am, Gaidano, G, Vitolo, U, Morra, E., Tedeschi, A, Picardi, P, Ferrero, S, Benevolo, G, Margiotta Casaluci, G, Varettoni, M, Baratè, C, Motta, M, Gini, G, Goldaniga, Mc, Visco, C, Zaja, Francesco, Belsito Petrizi, V, Ravelli, E, Gentile, M, Urbano, Ma, Franceschetti, S, Ghione, P, Orsucci, L, Frustaci, Am, Gaidano, G, Vitolo, U, and Morra, E.

Subjects
Bendamustine, Male, medicine.medical_specialty, Cancer Research, Salvage therapy, Aggressive lymphoma, Neutropenia, Gastroenterology, rituximab, salvage, Recurrence, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Medicine, Bendamustine Hydrochloride, Humans, Aged, Retrospective Studies, Waldenström macroglobulinemia, Aged, 80 and over, Salvage Therapy, business.industry, Secondary Myelodysplastic Syndrome, refractory, relapsed, Female, Follow-Up Studies, Middle Aged, Retreatment, Rituximab, Treatment Outcome, Waldenstrom Macroglobulinemia, Hematology, Oncology, Waldenstrom macroglobulinemia, medicine.disease, Surgery, business, Diffuse large B-cell lymphoma, medicine.drug
Abstract

According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m(2) day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m(2)). Patients had previously received a median number of 2 lines of treatment (range 1-5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients' characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3-54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

Published
2015

64. A revised international prognostic score system for Waldenström’s macroglobulinemia

Author

Gavriatopoulou, M., primary, Kastritis, E., additional, Morel, P., additional, Duhamel, A., additional, Kyrtsonis, M.C., additional, Durot, E., additional, Symeonidis, A., additional, Laribi, K., additional, Hatjiharisi, E., additional, Ysebaert, L., additional, Vassou, A., additional, Giannakoulas, N., additional, Merlini, G., additional, Repousis, P., additional, Varettoni, M., additional, Michalis, E., additional, Hivert, B., additional, Michalis, M., additional, Leblond, V., additional, and Dimopoulos, M.A.C., additional

Published
2018
Full Text
View/download PDF

65. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

Author

Arcaini, L, Vallisa, D, Rattotti,S, Ferretti,VV, Ferreri,AJM, Bernuzzi,P, Merli,M, Varettoni,M, Chiappella,A, Ambrosetti,A, Tucci,A, Rusconi,A, Visco,S, Spina,L, Cabras,G, Luminari,S, Tucci,M, Musto,P, Ladetto,M, Merli,F, Stelitano,C, d’Arco,A, Rigacci,L, Levis,A, Rossi,D, Spedini,P, Marino, D Bruno, R, Baldini, L, Pulsoni,A, MANCUSO, Salvatrice, Arcaini, L, Vallisa, D, Rattotti,S, Ferretti,VV, Ferreri,AJM, Bernuzzi,P, Merli,M, Varettoni,M, Chiappella,A, Ambrosetti,A, Tucci,A, Rusconi,A, Visco,S, Spina,L, Cabras,G, Luminari,S, Tucci,M, Musto,P, Ladetto,M, Merli,F, Stelitano,C, d’Arco,A, Rigacci,L, Levis,A, Rossi,D, Spedini,P, Mancuso,S, Marino,D Bruno,R, Baldini, L, and Pulsoni,A

Subjects
Antiviral Treatment, indolent B cell lymphoma,HCv infection
Published
2014

66. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia

Author

Castillo, J.J. Garcia-Sanz, R. Hatjiharissi, E. Kyle, R.A. Leleu, X. McMaster, M. Merlini, G. Minnema, M.C. Morra, E. Owen, R.G. Poulain, S. Stone, M.J. Tam, C. Varettoni, M. Dimopoulos, M.A. Treon, S.P. Kastritis, E.

Abstract

The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM. © 2016 John Wiley & Sons Ltd

Published
2016

67. Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia

Author

Castillo, JJ, Garcia-Sanz, R, Hatjiharissi, E, Kyle, RA, Leleu, X, McMaster, M, Merlini, G, Minnema, MC, Morra, E, Owen, RG, Poulain, S, Stone, MJ, Tam, C, Varettoni, M, Dimopoulos, MA, Treon, SP, Kastritis, E, Castillo, JJ, Garcia-Sanz, R, Hatjiharissi, E, Kyle, RA, Leleu, X, McMaster, M, Merlini, G, Minnema, MC, Morra, E, Owen, RG, Poulain, S, Stone, MJ, Tam, C, Varettoni, M, Dimopoulos, MA, Treon, SP, and Kastritis, E

Abstract

The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.

Published
2016

69. Long Term Toxicity and Follow-up of Waldenstrom's Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab

Author

Tedeschi, A, Picardi, P, Goldaniga, M, Casaluci, G, Benevolo, G, Ferrero, S, Varettoni, M, Barate, C, Gini, G, Visco, C, Motta, M, Petrizzi, V, Zaja, F, Ravelli, E, Gentile, M, Frustaci, A, Orsucci, L, Morra, E, Gaidano, G, Cairoli, R, Goldaniga, MC, Casaluci, GM, Petrizzi, VB, Frustaci, AM, Tedeschi, A, Picardi, P, Goldaniga, M, Casaluci, G, Benevolo, G, Ferrero, S, Varettoni, M, Barate, C, Gini, G, Visco, C, Motta, M, Petrizzi, V, Zaja, F, Ravelli, E, Gentile, M, Frustaci, A, Orsucci, L, Morra, E, Gaidano, G, Cairoli, R, Goldaniga, MC, Casaluci, GM, Petrizzi, VB, and Frustaci, AM

Published
2015

70. Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials

Author

Guerrera, M, Varettoni, M, Tedeschi, A, Frustaci, A, Ferretti, V, Arcaini, L, Picardi, P, Zibellini, S, Rattotti, S, Cairoli, R, Cazzola, M, Guerrera, ML, Frustaci, AM, Ferretti, VV, Guerrera, M, Varettoni, M, Tedeschi, A, Frustaci, A, Ferretti, V, Arcaini, L, Picardi, P, Zibellini, S, Rattotti, S, Cairoli, R, Cazzola, M, Guerrera, ML, Frustaci, AM, and Ferretti, VV

Published
2015

72. Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry

Author

Merli, M, Arcaini, L, Boveri, E, Rattotti, S, Picone, C, Passamonti, Francesco, Tenore, A, Sozzani, L, Lucioni, M, Varettoni, M, Rizzi, S, Morello, L, Ferretti, V, Pascutto, C, Paulli, Marco, and Lazzarino, M.

Subjects
Non-Hodgkin lymphoma, bone-marrow biopsy, flow cytometry, Bone Marrow, Lymphoma, Non-Hodgkin, Histological Techniques, Humans, Bone Marrow Examination, Lymphoma, Large B-Cell, Diffuse, Waldenstrom Macroglobulinemia, Flow Cytometry, Lymphoma, Follicular, Retrospective Studies
Abstract

Bone marrow (BM) examination is essential in the staging of non-Hodgkin's lymphoma (NHL) patients. Few studies have compared BM histologic findings with results of flow cytometric (FC) analysis. We analyzed the incidence and patterns of histologic BM involvement in a series of 753 patients with NHL. For 498 patients, a concurrent FC analysis on BM was available. Histologic involvement was detected at diagnosis in 311/753 (41%) patients. By FC, BM involvement was clearly detected in 150/498 (30%). After excluding 12 cases with equivocal histology, concordance between the two methods was detected in 411 (85%) cases (27% BMB+/FC+; 58% BMB-/FC-), while discordance was present in 75 (15%) (P0.001): 58 cases (12%) were BMB+/FC- and 17 (3%) were BMB-/FC+. Discordance was more frequent in FL and in lymphoplasmacytic lymphoma (LPL). These data demonstrate that the two methods are comparable in qualitative assessment of BM involvement in NHL, with the exception of FL and LPL. In FL, diffuse large B-cell lymphoma (DLBCL) and LPL, FC underestimates the extent of infiltrate with respect to histology.

Published
2010

73. The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection

Author

Arcaini, L., primary, Rossi, D., additional, Lucioni, M., additional, Nicola, M., additional, Bruscaggin, A., additional, Fiaccadori, V., additional, Riboni, R., additional, Ramponi, A., additional, Ferretti, V. V., additional, Cresta, S., additional, Casaluci, G. M., additional, Bonfichi, M., additional, Gotti, M., additional, Merli, M., additional, Maffi, A., additional, Arra, M., additional, Varettoni, M., additional, Rattotti, S., additional, Morello, L., additional, Guerrera, M. L., additional, Sciarra, R., additional, Gaidano, G., additional, Cazzola, M., additional, and Paulli, M., additional

Published
2014
Full Text
View/download PDF

74. Bortezomib with HIG-dose dexamethasone as first line therapy in patients with multiple myeloma candidates to high-dose therapy

Author

Corso, A, Barbarano, L, Mangiacavalli, S, Montalbetti, L, Brasca, P, Zappasodi, P, Carella, A, Spriano, M, Alessandrino, E, Cairoli, R, Petro, D, Varettoni, M, Bernasconi, P, Lazzarino, M, Morra, E, Alessandrino, EP, Corso, A, Barbarano, L, Mangiacavalli, S, Montalbetti, L, Brasca, P, Zappasodi, P, Carella, A, Spriano, M, Alessandrino, E, Cairoli, R, Petro, D, Varettoni, M, Bernasconi, P, Lazzarino, M, Morra, E, and Alessandrino, EP

Abstract

Introduction: A phase II multi-center study was performed to investigate the efficacy of Bortezomib with high-dose dexamethasone (Vel-Dex) as induction therapy in multiple myeloma (MM) patients (pts) candidates to high-dose therapy. Methods: Patients were planned to receive 4 courses of Vel-Dex (Bortezomib 1.3 mg/m2 i.v. on days 1, 4, 8, 11; oral Dexamethasone 40 mg on days 1–4 and 8–11 every 3 weeks), followed by 2 courses of DCEP 4 weeks apart with stem cell collection, and a single autologous transplant with melphalan 200 mg/m2. Patients were untreated, aged ≤65 years, with Durie-Salmon stage III, II, or I in progression. Criteria of response were: CR: negative serum/urine immunofixation with <5% bone marrow plasmacytosis (BMPC); nCR: positive serum/urine immunofixation with <5% BMPC; VGPR/PR: reduction of at least 90%/50% of serum/urine monoclonal component (MC), and of BMPC. Adverse events (AE) were graded by the NCI-CTC version 3.0. Mann-Whitney U test was used to correlate response and main prognostic parameters. Results: From March 2006 to June 2007, 52 out of the 54 planned pts entered the protocol. Patient characteristics at enrolment were: male/female 33/19; median age 57 years (37–65); IgG/IgA/light-chain 33/9/10 pts; stage III/II/I in progression 44/5/3 pts; ISS I/II/III 21/14/17 pts; cytogenetic analysis showed del 13 in 54%, t (4;14) in 15%. Thirty-nine of 52 enrolled pts are evaluable for efficacy and toxicity after 4 Vel-Dex courses. Six pts were withdrawn (3 for progression, 2 for toxicity, 1 patient withdrew informed consent). Overall response rate (ORR) was 85%, with 67% major responses (CR 33%, nCR 26%, VGPR 8%), PR 18%, stable disease 7%, progression 8%. No statistically significant correlation was found between response and either age, stage, ISS, or unfavorable cytogenetics. Friedman ANOVA (p=0.00001) and Wilcoxon Matched Pairs (p<.05) tests showed a statistically significant progressive decrease of serum MC after each Vel-Dex cycle.

Published
2007

76. Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma

Author

Zibellini, S., primary, Capello, D., additional, Forconi, F., additional, Marcatili, P., additional, Rossi, D., additional, Rattotti, S., additional, Franceschetti, S., additional, Sozzi, E., additional, Cencini, E., additional, Marasca, R., additional, Baldini, L., additional, Tucci, A., additional, Bertoni, F., additional, Passamonti, F., additional, Orlandi, E., additional, Varettoni, M., additional, Merli, M., additional, Rizzi, S., additional, Gattei, V., additional, Tramontano, A., additional, Paulli, M., additional, Gaidano, G., additional, and Arcaini, L., additional

Published
2010
Full Text
View/download PDF

77. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients

Author

Passamonti, F., primary, Rumi, E., additional, Arcaini, L., additional, Boveri, E., additional, Elena, C., additional, Pietra, D., additional, Boggi, S., additional, Astori, C., additional, Bernasconi, P., additional, Varettoni, M., additional, Brusamolino, E., additional, Pascutto, C., additional, and Lazzarino, M., additional

Published
2008
Full Text
View/download PDF

81. Report of Consensus Panel 3 from the 11thInternational Workshop on Waldenström's Macroglobulinemia: Recommendations for Molecular Diagnosis in Waldenström's Macroglobulinemia

Author

Garcia-Sanz, R, Varettoni, M, Jiménez, C, Ferrero, S, Poulain, S, San-Miguel, JF, Guerrera, ML, Drandi, D, Bagratuni, T, McMaster, M, Roccaro, AM, Roos-Weil, D, Leiba, M, Li, Y, Qiu, L, Hou, J, De Larrea, C Fernandez, Castillo, JJ, Dimopoulos, M, Owen, RG, Treon, SP, and Hunter, ZR

Abstract

Apart from the MYD88L265Pmutation, extensive information exists on the molecular mechanisms in Waldenström's Macroglobulinemia and its potential utility in the diagnosis and treatment tailoring. However, no consensus recommendations are yet available. Consensus Panel 3 (CP3) of the 11thInternational Workshop on Waldenström's Macroglobulinemia (IWWM-11) was tasked with reviewing the current molecular necessities and best way to access the minimum data required for a correct diagnosis and monitoring. Key recommendations from IWWM-11 CP3 included: 1) molecular studies are warranted for patients in whom therapy is going to be started; such studies should also be done in those whose bone marrow (BM) material is sampled based on clinical issues; 2) molecular studies considered essential for these situations are those that clarify the status of 6q and 17p chromosomes, and MYD88, CXCR4, and TP53genes. These tests in other situations, and/or other tests, are considered optional; 3) independently of the use of more sensitive and/or specific techniques, the minimum requirements are Allele Specific Polymerase Chain Reaction for MYD88L265Pand CXCR4S338Xusing whole BM, and Fluorescence in situ hybridization for 6q and 17p and sequencing for CXCR4and TP53using CD19+ enriched BM; 4) these requirements refer to all patients; therefore, sample should be sent to specialized centers.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results